Searched for
ILLUMYA
Outlook on healthcare sector; Sun Pharma, Granules could give 18-20% return in 12 monthsThe YoY growth of both Indian pharma companies and MNCs experienced a revival in July ’23. Indian pharma companies grew 7% YoY, while MNC p...- Sun Pharma Q3 Preview: Sales likely to rise but profit may fall YoYAccording to an ETNow poll, the drugmaker’s consolidated revenue for the quarter ended December is seen rising 12.5% on-year to Rs 11,100 c...
- Does Sun Pharma's specialty portfolio hold key to its performance?According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. ...
- Brokerages up price targets on rising Sun, some point to cloudsMotilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edel...
- Positive on Sun Pharma numbers, specialty focus: Ashika Stock BrokingIf I adjust the numbers for Taro (a very poor number with 75% decline year on year), then overall the numbers look good to me.
- Sun Pharma Q3 results preview: Profit likely to fall up to 16%Kotak Securities expects 16.4 per cent drop in profit at Rs 1,036.50 crore.
- Sun Pharma climbs over 3% after USFDA drug nodThe company informed stock exchanges about the USFDA nod after market hours of Wednesday.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharma gets USFDA nod for plaque psoriasis drugThe FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
Load More
